Devotion to innovation, compassion for patients, artificial intelligence for cancer care
Evidence-driven precision medicine is becoming a game changer in cancer treatment. Data curation referring to genomics, pathomics, radiomics along with clinical outcomes harnessing artificial intelligence provide predictive mechanisms to assess response to treatment as well as to determine optimal treatment plans. Our vision is to introduce the first, self-contained, self-trained paradigm to thrive cancer research and treatment in a new dimension targeting drug development, treatment selection, treatment assessment and optimization of clinical outcomes. We offer a new/fully holistic approach for cancer research & treatment referring to macro/micro/nano scale integration of medicine, information theory and computational medicine.
TheraPanacea is a highly ambitious artificial intelligence-powered French spinoff medical technology company exploiting state-of-the-art research technology with origins from Ecole CentraleSupelec, Inria and Gustave Roussy Institute. TheraPanacea brings to the radiation therapy market the latest inter-disciplinary technological advances from the associated research laboratories – which are among the most renowned internationally in their core disciplines (machine learning, AI, advanced mathematics) - endowed with an excellent IP portfolio (international patents & protected software) and validated at the proof of concept level through prestigious clinical collaborations, e.g. Gustave Roussy Institute. Our ART-Plan solution is the first fully AI powered solution to deliver radiation therapy on the fly and currently consists of the following product:
- ART-Plan.annotate: Automatic contouring of tumor and surrounding organs through anatomy preserved deep multi-atlas learning [CE marked]
Our Technologies / Intellectual Property Portfolio / Partners
TheraPanacea is a spinoff of the Ecole CentraleSupelec - one of the most prestigious engineering schools / "Grandes Ecoles" of France - that is the school of engineering of the University of Paris-Saclay. It exploits research/intellectual portfolio carried out in the fields of machine learning/optimization, computer vision/medical imaging and artificial intelligence in one of the world leading laboratories in these areas.
Our intellectual portfolio was built through of massive research investment of more than 10 mEU - from European, National & Industrial grants - during the last decade. Harnessing scientific excellence for cancer care is our approach for disruptive/cutting-edge innovation. In order to position ourselves as the leading innovative care in the field of cancer care, we adopt a collaboration/structured/premium research approach with:
Gustave Roussy is the premier European Cancer Center. It is a unique facility for patient care, research and higher education. It deploys cutting-edge research with the aim of making major discoveries, personalized & minimally invasive medicine and developing novel/innovative pathways to offer patients optimal care.
CentraleSupélec is an internationally-reputed Higher Education and Research Institution, funding member of the University of Paris-Saclay and its school of engineering. It has campus in three continents (Europe (FR), Asia (CN, IN) & Africa (MC)). Its excellence lies in its combination of fundamental and applied sciences for innovation with societal impact.
Professor Nikos Paragios (Chief Executive Officer & Scientific Director) holds a PhD in electrical engineering from Inria (2000). Nikos has more than 25 years of international experience on cutting level research with 300+ publications and 25 patents. He is fluent in English & French and native in Greek.
Catherine Huynh (Chief Operating Officer) holds a M.Eng from INP-Grenoble (1988) in nuclear engineering. Catherine has more than 15 years of international experience on management of digital transformation projects She is fluent in English & Mandarin and native in French.
Rafael Marini-Silva (Lead, Development) holds a MSc in machine larning from Ecole normale supérieure Paris-Saclay (2011). He has 10 years of experience on software development. He is fluent in English & French and native in Portuguese.
Norbert Bus (Lead, Engineering) holds a PhD from Université Paris-Est (2015) in computer science. Norbert has more than ten years of experience in engineering and research in the public and private sector. He is fluent in English & German and native in Hungarian.
Catherine Nemoz (Sales & Marketing director) holds a MSc in biomecanics from Université de Strasbourg (1996). Catherine has more than 15 years of international experience on leading commercialization efforts in radiation oncology domain. She is fluent in English and native in French.
Aurelien Lombard (Lead, R&D engineer) holds a MEng in applied mathematics from Ecole Centrale Paris (2015). He is fluent in English and native in French.
Emilie Alvarez - (PhD student - pursuing in collaboration with IGR) holds a MSc in medical physics from the University of Paris-Sud (2016). Se is fluent in English and native in French.
Benjamin Angelard (R&D engineer) holds a MSc in computer science from the University of Boston (2018) and a Msc in Artificial Intelligence from Epita (2018). He is fluent in English and native in French.
Thierry Boule (R&D engineer) holds a PhD in medical physics from the Universidad de Sevilla (2007). He is fluent in English & Spanish and native in French.
Cindy Chassang (Ergonomist, Quality Insurrance) holds a MSc in cognitive science from the Université Lumière (Lyon II) (2017). She is fluent in English and native in French.
Michalis Chatzizacharias (software developer) holds a MEng in computer science from the Technological Educational Institute of Crete (2017). He is fluent in English and native in Greek.
Nina Dissler (Clinical Analyst & application engineer) holds a M.Eng in & Grenoble INP - Phelma abd MSc in applied mathematics from Ecole Polytechnique Montréal (2019). She is fluent in English & native in French.
Sibylle De Vandiere (clinical and application engineer) holds a MEng from Arts et Métiers ParisTech & Karlsruher Institut für Technologie (KIT) (2018). Sheis fluent in English & German and native in French.
Rutger Fick (R&D engineer) holds a PhD in electrical engineering from Inria (2017). He is fluent in English & French and native in Dutch.
Francois Henri (Architect, Sales) holds a M.Sc from Essec Business School in Executive Management and Business Administration (2013). He is fluent in English and native in French.
Sonia Martinot - (PhD student - pursuing in collaboration with CentraleSupelec IGR) holds a MEng in applied mathematics from Ecole CentraleSupelec, University of Paris-Saclay (2019). She is fluent in English and native in French.
Antoine Pouille (R&D engineer) holds a MSc in computer science from École normale supérieure de Lyon (2016). He is fluent in English and native in French.
Eugenie Ullmann (Clinical Analyst & Data Manager) holds a MEng in Bio-Technologies from Ecole Centrale Lyon (2013). She is fluent in English and native in French.
Our Scientific Board
Dr. Nicholas Ayache, Inria & French Academy of Sciences, FR
Pr. Eric Deustch, Gustave Roussy & University Paris Sud, FR
Pr. Benoit Gallix, Director IHU/University of Strasbourg, FR
Pr. Eric Lartigau, Oscar Lambret/University of Lille, FR
Pr. William Wells, MIT & Harvard Medical School, USA
Investors / Institutional Support
Awards / Distinctions
City of Paris
Great Innovation Award in Health Tech (2017)
First Innovation Award in Radiology (2018)
Great Innovation Award in Artificial Intelligence (2018)